Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Activiomics Signs Research Agreement with Kyowa Hakko Kirin

Published: Friday, November 23, 2012
Last Updated: Friday, November 23, 2012
Bookmark and Share
Company signs agreement as part of its strategic partnership with BioFocus.

Activiomics has announced that it has signed a research agreement with the Japanese pharmaceutical company Kyowa Hakko Kirin.

Under the agreement, Activiomics will apply its novel TIQUAS phosphoproteomics platform to elucidate signalling mechanisms of lead compounds in relevant cell-based systems.

This agreement was signed as part of Activiomics’ recently announced strategic partnership with BioFocus.

Activiomics partners with Pharma and Biotech using its innovative mass spectrometry based methods to analyze and interpret cell signalling pathway activity, generating high value information for the pharmaceutical and biotechnology industry.

“We’ve engaged with Activiomics because we recognize that Activiomics’ label free phosphoproteomics approach can provide unique insights into signalling pathway activity, information that can complement and extend our existing gene expression datasets. This technology will enable us to better understand cell signalling mechanisms of our lead compounds and could enable us to identify important biomarkers” said Etsuo Ohshima, Ph.D., managing officer and vice president, head, research division at Kyowa Hakko Kirin.

Dr Neil Torbett, COO of Activiomics, said: “We are delighted to have signed this agreement with Kyowa Hakko Kirin. This is a further endorsement of our technology platform and also represents Activiomics’ first entry into the Japanese market. Activiomics has received invaluable support from BioFocus in establishing this collaboration, a clear demonstration of our strategic partnership in action”.

Dr Chris Newton, Managing Director of BioFocus, commented “BioFocus is pleased to have participated in the signing of this deal, which we intend to be the first of many. Future deals will add together BioFocus’ drug discovery capabilities and Activiomics’ phosphoproteomics platform for the furtherance of our clients’ projects”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Activiomics Extends Agreement with Kyowa Hakko Kirin
Activiomics announced it has extended its Contract Research Agreement with Japanese pharmaceutical company Kyowa Hakko Kirin (KHK) by entering into a new research programme.
Thursday, September 19, 2013
Scientific News
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Coding and Computers Help Spot Methane, Explosives
Coded apertures improve and shrink mass spectrometers for field use.
Why Bearcats Smell Like Buttered Popcorn
Researchers pinpoint chemical compound that gives rare animal its popcorn-like scent.
UCSD Scientists Receive NIH Grant to Combat Antibiotic Resistance
Interdisciplinary program will use systems biology approaches to understand how antibiotics work in concert with patient’s immune system.
Virus Causing Tilapia Die-Offs Identified
Discovery of the virus causing Tilapia die-offs in Israel and Ecuador points the way to protecting a fish that feeds multitudes.
Novel Collagen Fingerprinting Identifies A Neanderthal
Study from the universities of Oxford and Manchester uses ZooMS technique to identify traces of an extinct human.
Hope for Combating Muscular Dystrophy
Decoding a sugar molecule and identifying a mechanism linking it to MS could help in the development of therapy for the disease.
Decoding Sugar Molecules Offers New Key For Combating Muscular Dystrophy
Japanese scientists find a rare sugar unit called ribitol 5-phosphate within the sugar molecules on the surface of muscle cells. Mutations in 3 genes linked to muscular dystrophy affect the creation of this sugar molecule.
A Vision for Precision Medicine
The University of Manchester and the University of Dundee partner to share disease screening data.
New Targets for Diabetes, Inflammation Discovered
The Scripps Research Institute and Salk Scientists discover 'outlier' enzymes that could offer new targets to treat diabetes and inflammation.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!